Articles tagged with Neurodegenerative Diseases
Researchers discovered a two-step mechanism where inhibitory neurons release nitric oxide to rapidly dilate blood vessels, followed by slower, localized vasodilation via astrocyte activation. This breakthrough sheds light on how neural signals are translated into blood volume changes in brain imaging.
Research reveals insulin resistance and dysglycemia contribute to Alzheimer's disease progression, affecting cognitive function. The study identifies new gold standards for clinical care practice, including metformin and other glucose-lowering agents.
Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.
Long-haul COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome share similar pathophysiologies, including oxidative stress, autoantibodies, and impaired mitochondrial energy conversion. These conditions also exhibit neurodegenerative outcomes, such as fatigue, sleep disturbances, and increased risk of dementia.
Researchers now have access to high-value datasets that could transform our understanding of Parkinson’s and other neurodegenerative diseases. Data from 3 million human cells across 9 brain regions will help explore the brain at unprecedented resolution.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.
An international team has uncovered a new mechanism by which mitochondria and peroxisomes work together to defend against oxidative stress, maintaining cellular health. This discovery challenges the long-standing idea that cellular defense is confined within individual compartments.
Researchers identified four distinct pathways leading to Alzheimer's disease, revealing how conditions progress step-by-step toward the condition. The study validated findings in a nationally diverse population, suggesting that understanding these pathways could fundamentally change how clinicians approach early detection and prevention.
Professor Eran Meshorer's groundbreaking research in epigenetics and stem cell biology has uncovered critical insights into chromatin structure and gene expression. His work has broad implications for regenerative medicine, developmental biology, and understanding neurological disorders.
Researchers at UCLA Health have made a groundbreaking discovery about the mechanisms underlying vascular dementia. They found that targeting inflammation in brain blood vessels can promote brain repair and functional recovery in mice. This breakthrough highlights a potential new treatment approach for this understudied form of dementia.
Researchers discovered lower α-synuclein levels in red blood cells of patients with Dementia with Lewy Bodies, a potential biomarker for early diagnosis. This finding may contribute to improving treatment outcomes and patient care for those affected by DLB.
A study reveals that ultra-small nanoparticles can induce abnormal protein conformation and have the potential to cause pathological conditions like Alzheimer's disease. The researchers used spectroscopy-based experiments to analyze the interactions between bovine serum albumin and silica nanoparticles.
A new brain imaging benchmark may improve how researchers classify biologically meaningful changes associated with Alzheimer’s disease. Researchers found a tau cut-point that distinguished individuals with cognitive impairment from those aging normally, but its effectiveness was limited in non-Hispanic Black participants.
The new centre will investigate neural dynamics, developing novel interventions and devices to improve symptom relief and quality of life for people with brain disorders. It aims to harness neural dynamics for people with conditions like Parkinson’s disease or epilepsy.
Researchers at the University of Sydney have identified a new brain protein involved in Parkinson's disease and found that targeting it with a drug treatment improved motor function in experimental models. The study suggests that this approach could slow or stop the progression of Parkinson's disease in humans.
Researchers analyzed single-cell transcriptomes from early, middle, and late stages of AD to identify subtle shifts in cellular activity. They found that mitochondria in vulnerable brain areas began to fail early in the disease, even before amyloid plaque buildup. The study also identified a gene called MEG3 involved in regulating mito...
Researchers suggest that brains reach a critical state to learn, remember, and think, which can be measured using fMRI technology. This framework offers a new perspective on neurological diseases like Alzheimer's, which disrupt the brain's ability to maintain criticality.
Researchers have discovered that a rare genetic mutation delays Alzheimer's disease by suppressing inflammatory signaling in the brain. The study found that inhibiting this pathway with a drug-like inhibitor replicated key protective effects of the mutation in a preclinical model.
Pernilla Wittung-Stafshede joins Rice University's Department of Chemistry as a professor, bringing expertise in metalloproteins and protein aggregation to enhance cancer research. Her focus is on understanding the role of copper-binding proteins in cancer metastasis and potential future therapies.
Researchers at La Jolla Institute for Immunology discovered that T cell reactivity is highest during the prodromal period in Parkinson's disease, which can last for decades before noticeable symptoms. This finding may guide the development of early diagnostic tools and provide a new timeline for Parkinson's disease detection.
Research found that approximately 50% of participants with late-life depression and bipolar disorder showed tau accumulation in their brains, compared to only about 15% of healthy controls. The study suggests that neurodegenerative diseases, including Alzheimer's, can initially manifest as psychiatric symptoms.
Researchers developed a digital motor score, HDDMS, using smartphone apps to track disease progression in Huntington's disease. The HDDMS is around twice as sensitive as the current clinical measure, allowing for more efficient clinical trials and potentially accelerating drug development.
Researchers from the Mount Sinai Health System are presenting new studies on the impact of sleep on neurodegenerative diseases like Alzheimer's. The studies explore the relationship between obstructive sleep apnea and Alzheimer's pathogenesis, as well as the effects of sleep disruption on spatial learning and neuroinflammation.
Researchers discovered how VCP, an enzyme that unravels proteins, interacts with tag-removing enzymes DUBs to regulate protein degradation. This interaction may have implications for treating neurodegenerative disorders like Alzheimer's and certain cancers.
Dr. Vanessa Casha, a postdoctoral scholar at the UCLA Brain Research Institute, received the 2025 Hereditary Disease Foundation's Nancy S. Wexler Young Investigator Prize for her research on Huntington's disease. She aims to identify key proteins driving the disease and potential therapeutic targets.
Researchers identified novel truncated RNAs from jumping genes that encode reverse transcriptases in the aging human brain, particularly in neurons. This discovery may provide new insights into Alzheimer's disease and potential therapeutic targets.
A new study suggests that women who spend more time in their reproductive phase may experience slower brain aging. Estradiol, the most potent form of estrogen during this period, may help protect the brain from age-related decline. However, further research is needed to fully understand the relationship between estradiol and brain health.
Researchers have discovered a new method to enhance brain waste clearance by precisely stimulating the lymphatics under skin on the neck and face. This non-invasive approach may offer a safer alternative to current treatments for age-related neurological disorders, such as Alzheimer's disease.
Old neurons exhibit unique defects resulting from molecular stress, making them more vulnerable to neurodegeneration. The study sheds light on the molecular mechanisms behind brain cell deterioration, which could lead to new therapies for preventing neurodegenerative diseases.
A new study found that adopting the MIND diet is linked with reduced dementia risk, even among older adults. Those who improved their adherence to the diet over time showed a greater pattern of risk reduction.
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.
Researchers at UT Health San Antonio discovered associations between blood lipid levels and Alzheimer's disease risk. Higher small dense cholesterol particles increased risk, while ApoB48 levels were associated with lower risk.
Researchers from Florida Atlantic University have discovered a potentially safer treatment for multiple disorders linked to altered dopamine signaling by blocking the kappa opioid receptor. The study found that this approach can correct behavioral deficits and normalize dopamine availability.
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
A new study from the University of Georgia finds that rural counties in Georgia lack access to PET scan facilities and lecanemab infusion centers, making it difficult for patients to receive diagnosis and treatment. The researchers highlight the need for increased resources and support for rural patients with Alzheimer's disease.
Researchers used a new fMRI analysis method to measure cerebrovascular reactivity in 53 adults aged 51-83. They found an unexpected improvement in brain health in postmenopausal female participants, primarily in areas related to movement and memory.
The ATN dataset is a multi-cohort study that includes harmonised clinical and biomarker data from over 350 participants across ten European research cohorts. This dataset provides valuable insights into shared disease mechanisms among Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies.
Researchers have discovered a new drug that protects the blood-brain barrier, preventing neurodegeneration and cognitive impairment in Alzheimer's disease. The drug targets an enzyme that damages the BBB, which is also affected in traumatic brain injury and aging.
Researchers at UCLA Health identified a candidate small molecule, DDL-357, that increases concentrations of secreted clusterin, reducing toxic protein phospho-tau and improving mitochondrial function. The drug also improved memory in treated mice in maze-based cognitive tests.
Scientists at MIT have identified new potential targets for treating Alzheimer's disease, including a pathway involved in DNA damage repair. The study suggests that a combination of treatments targeting different cellular pathways may be more effective in blocking disease progression.
A protein complex has been identified that repairs abnormal DNA responsible for neurodegenerative disease Huntington's. This discovery could lead to the development of a therapeutic target to delay or prevent disease onset.
Research highlights potential link between microplastics in ultra-processed foods and brain health, with possible connections to depression and dementia. The studies propose a novel hypothesis connecting ultra-processed food consumption, microplastic exposure, and mental health outcomes.
Davis Joseph's groundbreaking discovery identifies a common master switch that can cure multiple brain-related diseases with a single method. The unified theory establishes that regulating axon-based 4E-BP2 protein deamidation can control disease progression.
The USC Parris Longevity Accelerator aims to develop early interventions for age-related diseases, including osteoarthritis and cardiovascular disease, through AI-driven diagnostic tools and targeted therapeutics. The initiative could lead to therapies that preserve mobility and restore strength in older adults.
Researchers at UC San Francisco have identified potential protein markers for frontotemporal dementia (FTD), a form of dementia affecting middle age. The study found changes in RNA regulation and brain connections that could lead to early diagnosis and targeted treatments.
Researchers found that astrocytes transmit signals, revealing new ways the brain processes information. The study provides direct evidence for the real-time action of astrocytes in live brains of fruit flies, suggesting their role in mediating neurophysiology and behavior.
A new technique using focused sound waves and microbubbles has shown great promise in treating debilitating brain lesions called cerebral cavernous malformations. The approach has halted the growth of lesions almost entirely, offering a potential paradigm shift in treatment.
Researchers at Mass General Brigham have pinpointed a 'sweet spot' for focused ultrasound treatment to provide significant relief from essential tremor. The study identified a specific subregion of the brain's thalamus that can result in optimal and long-lasting tremor improvements while reducing side effects. With this breakthrough, p...
Cognivue launches CARM, a novel metric predicting amyloid presence and enabling early Alzheimer's detection. The CARM score combines age with cognitive subtests to generate a four-point risk score indicating the likelihood of amyloid presence in the brain.
Scientists have developed a sugar-coated nanotherapy that effectively traps misfolded proteins, neutralizing their toxic effects on neurons. The treatment significantly boosts the survival of lab-grown human neurons under stress from disease-causing proteins.
Zhaoqi Yan, a scientist at Gladstone Institutes, has been awarded the 2025 Warren Alpert Distinguished Scholar fellowship to investigate the molecular mechanisms behind blood-brain barrier dysfunction. His research aims to develop new therapeutic strategies for neurological diseases, including Alzheimer's.
A new University of Georgia study found that Black Americans with high blood pressure and diabetes in midlife had significantly higher levels of a dementia-related biomarker over an 11-year period. Early intervention for these chronic health conditions could protect brain health and reduce neurodegenerative diseases later in life.
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
A new study reveals how a promising Parkinson's drug works by inhibiting the enzyme USP30, which prevents damaged mitochondria from being degraded. This breakthrough could lead to targeted therapies for Parkinson's disease and chronic kidney disease.
A study published in JAMA Neurology found no evidence supporting a diagnosis of the New Brunswick neurological syndrome of unknown cause, highlighting the need for independent clinical evaluations. The data revealed presence of several neurodegenerative and non-neurodegenerative conditions instead
Alzheimer's disease and other dementias are rising rapidly in China due to population growth and high-risk factors like high blood sugar, smoking, and obesity. The study projects continued rise unless effective interventions are implemented.
A new study from Washington University School of Medicine found that 81% of participants would choose to know their theoretical risk, but only 60% opted for real results. The research highlights the importance of considering ethical concerns and ensuring participants truly want their research results.
The MED13L Foundation has launched a three-year natural history study at Boston Children's Hospital to better understand MED13L Syndrome and inform future clinical trials. The study will collect data from 30 individuals with the condition over three years, providing valuable insights into disease progression and development.
Researchers discovered two proteins, GSK3ß and ERK1, that regulate the movement of a toxic huntingtin protein in neurons. Inhibiting GSK3ß led to reduced axonal blockages and neuronal cell death, while inhibiting ERK1 had the opposite effect, increasing transport problems and cell death.